Antibody Information

General Information of This Antibody

Antibody ID	ANI0PNOCN
Antibody Name	CCR4IL2
Antibody Type	Fusion protein (FP)
Antigen Name	C-C chemokine receptor type 4 (CCR4)	Antigen Info

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

CCR4-IL2 IT [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.45 pM	Positive CCR4 expression (CCR4 +++/++)
Method Description	A comparison of the in vitro efficacy of CCR4-IL2 IT versus brentuximab to human CD25+CCR4+CD30+ Hut102/6TG cells was performed using a luminescent-based cell viability assay.
In Vitro Model	Cutaneous T cell lymphoma	HUT102/6TG cells		Homo sapiens

References

Ref 1	CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model. FEBS Open Bio. 2023 Jul;13(7):1309-1319. doi: 10.1002/2211-5463.13625. Epub 2023 May 15.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.